115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
    Meeting Abstract

    Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial
    Meeting Abstract

    Gelderblom, H.; Bhadri, V. A.; Stacchiotti, S.; Bauer, S.; Wagner, A. J.; van de Sande, M.; Bernthal, N. M.; Lopez Pousa, A.; Abdul Razak, A. R.; Italiano, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: Results from PRIMA/ENGOT-OV26/GOG-3012
    Meeting Abstract

    González-Martín, A.; Pothuri, B.; Ginesta, M. P. B.; Graybill, W. S.; Vergote, I. B.; McCormick, C.; Mirza, M. R.; Moore, R. G.; Lorusso, D.; O'Cearbhaill, R. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients
    Meeting Abstract

    Montero, A. J.; Giordano, A.; Jhaveri, K.; Munster, P.; Rodon, J.; Lorusso, P.; Orr, D.; Bartolomé Arcilla, J.; Italiano, A.; Elias, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Ng, K.; Ou, F. S.; Zemla, T.; McCleary, N.; Kalyan, A.; Shusterman, M.; Vijayvergia, N.; Wu, C.; Cohen, S. A.; Pulsipher, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Meeting Abstract

    Schmid, P.; McArthur, H. L.; Cortés, J.; Xu, B.; Cardoso, F.; Casalnuovo, M. L.; Demirci, U.; Freitas, R.; Ghosh, J.; Hegg, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma
    Journal Article

    Gallitto, M.; Zhang, X.; De Los Santos, G.; Wei, H. J.; Fernández, E. C.; Duan, S. F.; Sedor, G.; Yoh, N.; Kokossis, D.; Angel, J. C.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Human TMEFF1 is a restriction factor for herpes simplex virus in the brain
    Journal Article

    Chan, Y. H.; Liu, Z. Y.; Bastard, P.; Khobrekar, N.; Hutchison, K. M.; Yamazaki, Y.; Fan, Q.; Matuozzo, D.; Harschnitz, O.; Kerrouche, N.; more...
    Nature (2024)

    Fulltext@MSK | Save
  • Population priors for matrix factorization
    Journal Article

    Salehi, S.; Nazaret, A.; Shah, S. P.; Blei, D. M.
    Transactions on Machine Learning Research (2024)

    Fulltext@MSK | Save